close

Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States and Europe. The company offers drug discovery services, including assay development and design; screening programs, which provide tools to identify active compounds during the lead discovery phases of drug discovery; libraries for screening and hit-to-lead programs; bioanalytical services for extraction and quantitation of drug and metabolites in biological fluids and tissues; and natural product services. Its drug discovery services also include lead optimization, a process of altering the chemical structure of a confirmed hit to identify an improved drug lead; medicinal chemistry to modify the structure of a hit compound to synthesize new molecules; computer-aided drug discovery services to identify novel hits or leads against selected therapeutic targets, as well as to support medicinal chemistry lead optimization programs; in vitro ADMET assays to evaluate and improve metabolism, bioavailability, pharmacology, and toxicology of compounds; and preparative chromatography, a separation service. The company's chemical development services include process research and development; custom synthesis; process safety assessment; high potency and controlled substances; building blocks database; IND support services; fermentation development and optimization; and chemical synthesis and manufacturing services. Its analytical services include impurity identification and structure elucidation; method development, qualification, and validation; preformulation and physical characterization; quality control; regulatory support; and stability services. The company also serves agricultural and fine chemical companies, contract chemical manufacturers, government research entities, and non-profit organizations. Albany Molecular Research was founded in 1991 and is based in Albany, New York.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	2.80
Volume	35840
Volume Avg	92600
52 Week High	5.55
52 Week Low	2.08
PE	N/A
PE (group average)	39
EPS Year	-1.08
EPS change Q/Q	-96.97%
EPS change Q/Q Yr ago	100%
EPS change Q/Q next Q est	-150%
EPS change Y/Y	-72.22%
REV change Q/Q	17.08%
REV change Q/Q Yr ago	15.42%
EPS next Q est	-0.02
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%